Results 61 to 70 of about 476,894 (337)

ILD CAUSED BY ANTIFIBROTIC AGENTS [PDF]

, 2023
Interstitial lung disease (ILD), as an adverse effect of certain drugs, leads to inflammation and damage in the walls of the alveoli, making it difficult for the alveoli to take up oxygen.
Goda, Mitsuhiro, Hamano, Hirofumi, Ishizawa, Keisuke, Miyata, Koji, Nawa, Hideki, Niimura, Takahiro, Yagi, Kenta, Zamami, Yoshito   +7 more
core  

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Vaccine Adverse Event Reporting System (VAERS) [PDF]

Updated Aug.

core   +3 more sources

Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data

Frontiers in Pharmacology, 2022
Background: Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS ...
Ming Ni, Ming Ni, Xue-Dong Yin, Xue-Dong Yin, Wen-Juan Hu, Na Zeng, Bin Zhao, Zhi-Ling Li   +7 more
doaj   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. [PDF]

, 2017
Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of ...
Abagyan, Ruben, Atayee, Rabia, Cohen, Isaac V, Makunts, Tigran   +3 more
core   +2 more sources

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Frontiers in Pharmacology
IntroductionAnxiety diagnoses have surged recently during and after the COVID-19 pandemic. Lorazepam is widely recognized for its efficacy in treatment of anxiety, as well as insomnia, etc.
Zhengkang Su, Zhengwei Huang, Xiaoyu Chen, Xiaoyu Chen, Xi Li   +4 more
doaj   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real‐world pharmacoepidemiology study of post‐marketing surveillance data

Cancer Medicine, 2020
Backgrounds Although kidney impairments have been reported following immune checkpoint inhibitors (ICIs) in clinical studies, there are few pharmacoepidemiology studies to compare the occurrences, clinical features, and prognosis of renal adverse effects.
Gang Chen, Yan Qin, Qian‐qian Fan, Bin Zhao, Dan Mei, Xue‐mei Li   +5 more
doaj   +1 more source